Page 78 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 2 Tumor Biology and Metastasis 57

30. Maher CA, Wilson RK: Chromothripsis and human disease: piec- 56. Sherr CJ, McCormick F: The RB and p53 pathways in cancer, Can-
ing together the shattering process, Cell 148:29–32, 2012. cer Cell 2:103–112, 2002.
31. Stephens PJ, Greenman CD, Fu B, et al.: Massive genomic rear- 57. Soussi T: The history of p53: a perfect example of the drawbacks of
VetBooks.ir rangement acquired in a single catastrophic event during cancer 58. Oliner JD, Kinzler KW, Meltzer PS, et al.: Amplification of a gene
scientific paradigms, EMBO Rep 11:822–826, 2010.
development, Cell 144:27–40, 2011.
32. Forment JV, Kaidi A, Jackson SP: Chromothripsis and cancer:
causes and consequences of chromosome shattering, Nat Rev Can- encoding a p53 associated protein in human sarcomas, Nature
358:80–83, 1992.
cer 12:663–670, 2012. 59. Niazi S, Purohit M, Niazi JH: Role of p53 circuitry in tumorigen-
33. Jarrett O, Onions D: Leukaemogenic viruses. In Whittaker JA, edi- esis: a brief review, Eur J Med Chem 158:7–24, 2018.
tor: Leukaemia, ed 2, Oxford, 1992, Blackwell. 60. Vogelstein B, Kinzler KW: P53 function and dysfunction, Cell
34. Balmain A, Brown K: Oncogene activation in chemical carcinogen- 70:525–526, 1992.
esis, Adv Cancer Res 51:147–182, 1988. 61. Sluss HK, Jones SN: Analysing p53 tumour suppressor functions in
35. Adams GE, Cox R: Radiation carcinogenesis. In Franks LM, Teich mice, Expert Opin Ther Targets 7:89–99, 2003.
NM, editors: The molecular and cellular biology of cancer, ed 3, New 62. Harris CC: P53 tumor suppressor gene: from the basic research
York, 1997, Oxford University Press. laboratory to the clinic—an abridged historical perspective, Carci-
36. Neil JC, Hughs D, McFarlane R, et al.: Transduction and rear- nogenesis 17:1187–1198, 1996.
rangement of the myc gene by feline leukemia virus in naturally 63. Joerger AC, Fersht AR: The p53 pathway: origins, inactivation in
occurring T cell leukemias, Nature 308:814–820, 1984. cancer, and emerging therapeutic approaches, Annu Rev Biochem
37. Onions DE, Lees G, Forrest D, et al.: Recombinant feline viruses 85:375–404, 2016.
containing the myc gene rapidly produce clonal tumours expressing 64. Nasir L, Rutteman GR, Reid SW, et al.: Analysis of p53 mutational
T-cell antigen receptor gene transcripts, Int J Cancer 40:40–45, 1987. events and MDM2 amplification in canine soft-tissue sarcomas,
38. Teich NM: Oncogenes and cancer. In Franks LM, Teich NM, edi- Cancer Lett 174:83–89, 2001.
tors: The molecular and cellular biology of cancer, ed 3, New York, 65. Nasir L, Burr P, Mcfarlane S, et al.: Cloning, sequence analysis and
1997, Oxford University Press. expression of the cDNAs encoding the canine and equine homo-
39. Tennent R, Wigley C, Balmain A: Chemical carcinogenesis. In logues of the mouse double minute 2 (mdm2) proto-oncogene,
Franks LM, Teich NM, editors: The molecular and cellular biology of Cancer Lett 152:9–13, 2000.
cancer, ed 3, New York, 1997, Oxford University Press. 66. Nasir L, Krasner H, Argyle DJ, et al.: A study of p53 tumour sup-
40. Huret JL, Senon S, Bernheim A, et al.: An atlas on genes and chro- pressor gene immunoreactivity in feline neoplasia, Cancer Lett
mosomes in oncology and haematology, Cell Mol Biol 50:805–807, 155:1–7, 2000.
2004. 67. Nasir L, Argyle DJ: Mutational analysis of p53 in two cases of Bull
41. Soto AM, Sonnenschein C: The somatic mutation theory of can- Mastiff lymphosarcoma, Vet Rec 145:23–24, 1999.
cer: growing problems with the paradigm? Bioessays 26:1097–1107, 68. Nasir L, Argyle DJ, McFarlane ST, et al.: Nucleotide sequence of a
2004. highly conserved region of the canine p53 tumour suppressor gene,
42. Ren R: Mechanisms of BCR–ABL in the pathogenesis of chronic DNA Sequence 8:83–86, 1998.
myelogenous leukaemia? Nat Rev Cancer 5:172–183, 2005. 69. Hanahan D, Weinberg RA: The hallmarks of cancer, Cell 100:57–
43. Huang M, Weiss WA: Neuroblastoma and MYCN, Cold Spring 70, 2000.
Harb Perspect Med 3:a014415, 2013. 70. Hanahan D, Weinberg RA: Hallmarks of cancer: the next genera-
44. Nasir L, Rutteman GR, Reid SWJ, et al.: Analysis of p53 muta- tion, Cell 144:646–674, 2011.
tional events and MDM2 amplification in canine soft-tissue sarco- 71. Bennett RL, Licht JD: Targeting epigenetics in cancer, Annu Rev
mas, Cancer Lett 174:83–89, 2001. Pharmacol Toxicol 58:187–207, 2018.
45. Mochizuki H, Breen M: Sequence analysis of RAS and RAF mutation 72. Morrow JJ, Bayles I, Funnell APW, et al.: Positively selected
hot spots in canine carcinoma, Vet Comp Oncol 15:1598–1605, 2017. enhancer elements endow osteosarcoma cells with metastatic com-
46. Crozier C, Wood GA, Foster RA, et al.: KRAS mutations in canine petence, Nat Med 24:176–185, 2018.
and feline pancreatic acinar cell carcinoma, J Comp Pathol 155:24– 73. Self-sufficiency in growth signals. In Schwab M, editor: Encyclope-
28, 2016. dia of cancer, Berlin, 2011, Springer.
47. Terragni R, Casadei Gardini A, Sabattini S, et al.: EGFR, HER-2 74. Pennati M, Cimino-Reale G, Gatti L, et al.: Strategies to
and KRAS in canine gastric epithelial tumors: a potential human strike survival networks in cancer, Crit Rev Oncol 21:269–308,
model? PLoS One 9:e85388, 2014. 2016.
48. Smith AJ, Smith LA: Viral carcinogenesis, Prog Mol Biol Transl Sci 75. López-Lago MA, Okada T, Murillo MM, et al.: Loss of the tumor
144:121–168, 2016. suppressor gene NF2, encoding merlin, constitutively activates
49. Chen Y, Williams V, Filippova M, et al.: Viral carcinogenesis: fac- integrin-dependent mTORC1 signaling, Mol Cell Biol 29:4235–
tors inducing DNA damage and virus integration, Cancers (Basel) 4249, 2009.
6:2155–2186, 2014. 76. Huang JJ, Blobe GC: Dichotomous roles of TGF-β in human can-
50. Smith AJ, Smith LA: Viral carcinogenesis. In Pruitt K, editor: Prog- cer, Biochem Soc Trans 44:1441–1454, 2016.
ress in molecular biology and translational science, Cambridge, 2016, 77. Dikic I, Elazar Z: Mechanism and medical implications of mam-
MA: Academic Press, pp 121–168. malian autophagy, Nat Rev Mol Cell Biol 19:349–364, 2018.
51. Weiss RA, Vogt PK: 100 years of Rous sarcoma virus, J Exp Med 78. Kimmelman AC: The dynamic nature of autophagy in cancer,
208:2351–2355, 2011. Genes Dev 25:1999–2010, 2011.
52. Mullins JI, Brody DS, Binari Jr RC, et al.: Viral transduction 79. Argyle D, Kitamura T: Targeting macrophage-recruiting chemo-
of c-myc gene in naturally occurring feline leukaemias, Nature kines as a novel therapeutic strategy to prevent the progression of
308:856–858, 1984. solid tumors, Front Immunol 9:2629, 2018.
53. Hino O, Kobayashi T, Mourning Dr, Alfred G: Knudson: the two‐ 80. Raposo TP, Beirão BC, Pang LY, et al: Inflammation and cancer: till
hit hypothesis, tumor suppressor genes, and the tuberous sclerosis death tears them apart, Vet J 205:161–174, 2015.
complex, Cancer Sci 10:5–11, 2017. 81. Hayflick L: Mortality and immortality at the cellular level. A
54. Weinberg RA: The retinoblastoma protein and cell cycle control, review, Biochemistry 62:1180–1190, 1997.
Cell 81:323–330, 1995. 82. Blasco MA, Funk W, Villeponteau B, et al.: Functional character-
55. Du W, Searle JS: The Rb pathway and cancer therapeutics, Curr ization and developmental regulation of mouse telomerase RNA,
Drug Targets 10:581–589, 2009. Science 269:1267–1270, 1995.